CX3CL1/Fractalkine(FK), a chemokine existing in both secreted and membrane anchored form, was reported to induce suppressive activities in tumor models. Here, we demonstrate for the first time the antitumor effects of FK in murine hepatocellular carcinoma (HCC) by constructing a FK eukaryotic expression vector (pIRES-FK) and transferring it into such tumor cells. Tumor rejection experiments were performed by injecting FK gene-modified murine HCC cell line (MM45T.Li) into immunocompetent mice, which significantly inhibited tumorigenicity or growth of MM45T.Li-FK cells. Immunohistochemistry examination and fluorescenceactivated cell sorting analyses revealed both CD4 + and CD8 + T cells infiltration within the tumor together with a marked increase of these cells in the peripheral blood. Splenic lymphocyte from mice treated with MM45T.Li-FK were effective in the induction of tumor-specific cytotoxic T cells . We also observed an increased production of IL-2 and IFN-g in MM45T.Li-FK tumor tissue. Our results suggest that transfer of the FK gene into tumor cells could elicit a specific antitumor immunity capable of inhibiting tumor growth which lead to increased survival of tumor-bearing hosts. FK should be considered as a chemokine suitable for cancer immunoprevention or gene therapy.
Introduction
Hepatocellular carcinoma (HCC) is one of the most common malignancies in Asian countries. 1 Resection, radiotherapy, chemotherapy and transplantation are therapies available for this disease, but the prognosis of patients with HCC is still poor because of recurrence and extrusive metastasis. Treatment of patients with HCC remains a clinical challenge in need for novel effective therapeutics. In this regard, recent developments in tumor immunology and biotechnology have made several feasible cancer gene therapies and immunotherapies available.
Chemokines are a superfamily of small, proinflammatory molecules that regulate leukocyte trafficking in the body. Approximately 50 chemokines have been identified to date, and they are classified into four subfamilies based on their conserved cysteine motifs such as C, CC, CXC and CX3C chemokines. [2] [3] [4] [5] In addition to chemoattraction, recent investigations have suggested a possible role of chemokines in tumor growth and metastasis and in host-tumor response. 6 Some chemokines appear to have tumorigenic and metastatic potential. [7] [8] [9] However, gene modification of chemokines was reported to play an important role in the induction of antitumor immunity in some animal neoplasms. [10] [11] [12] The C chemokine lymphotactin gene modified SP2/0 myeloma model indicated that lymphotactin has natural adjuvant activities that may augment antitumor responses via effects on both T cells and neutrophils and suggested this gene to be important in the transfer of immunotherapies for some cancers. 13 The gene encoding CC chemokine CCL21 modified dendritic cells to lead to a marked reduction in tumor burden with extensive mononuclear cell infiltration of the tumors in a murine model of spontaneous bronchoalveolar cell carcinoma. In this case, both innate natural killer and specific T-cell antitumor responses increased significantly. 14 The adenoviral-mediated gene transfer of the CXCL12/SDF-1 significantly inhibited tumor growth and attracted dendritic cells and CD8 + T cells within the tumor. Intratumoral administration of AdSDF-1A elicited tumor-specific cytotoxic T cells (CTLs). 15 Furthermore, CCL5/RANTES, CCL4/macrophage inflammatory protein-1 b (MIP-1b), CCL2/monocyte chemoattractant protein (MCP-1) and CXCL9/MIG also showed strong antitumor activity in solid tumor models. [16] [17] [18] [19] These results suggest that chemokines could mediate antitumor immunity by recruiting monocytes, DC, NK and T lymphocytes into tumor sites.
Fractalkine (CX3CL1, FK) is the sole member of the CX3C chemokine/receptor family with a transmembrane domain and a chemokine domain on top of a long mucin-rich stalk. 5, 20 The membrane-anchored form of FK can be cleaved from the cell membrane by proteolysis to yield soluble chemoattractant FK. [25] [26] [27] [28] In this study, we used FK eukaryotic expression vector (pIRES-FK) to transfer the mouse FK to the murine HCC cell line MM45T.Li, and then inoculated these cells into mice to test their antitumor activity. The pIRES-FKinduced local recruitment of immune cells and suppressed tumor growth. Our data demonstrate for the first time that transfer of the FK gene into tumor cells could elicit specific antitumor immunity to inhibit the growth of hepatocellular tumors and lead to improved survival of the tumor-bearing hosts. (Table 1 ). In determining CTL activity, no cytotoxicity against syngeneic P815 mastocytoma cells was observed with any of these induced lymphocytes (data not shown). Together, these data suggest that potent and specific CTLs were induced, which might have been involved in the antitumor response induced by the FK gene transfer.
Results

Fk expression by tumor cells modified by the FK gene
Cytokine production in vivo
Given that cytokines are essential mediators in the induction of antitumor immunity, we intended to determine the expression of these immunoregulatory cytokines produced by splenic lymphocytes. To this end, we found that spleen cells from MM45T.Li-FK inoculated mice produced significantly higher levels of IL-2 and IFN-g than such cells obtained from other mice inoculated with either MM45T.Li-mock or parental MM45 T.Li cells (Po0.01). This was not the case for IL-4 ( Figure 5 ). The increased Th1 cytokine production observed suggest that the antitumor cellular immunity in the tumorbearing host might have been induced efficiently in MM45T.Li-FK inoculated mice in contrast to mice inoculated with MM45T.Li-mock or parental MM45T.Li cells.
Discussion
We hypothesized that HCC cells genetically modified ex vivo to overexpress FK might be effective in eliciting sufficient antitumor immunity to reject tumors and suppress their growth. The rationale for this type of tumor immunotherapy is to induce chemoattraction of immune effector cells to the tumor microenvironment by FK chemokine gene therapy and then to activate these cells at the tumor site.
In this study, we demonstrate that immunization with tumor cells transfected with the gene encoding FK can suppress the growth of MM45 T.Li tumors and increase the survival of tumor-bearing mice. The antitumor effect achieved in this murine HCC model is based primarily on immunological mechanisms involving the chemoattraction and subsequent activation of both CD4 + and CD8 + T lymphocytes. Gene therapy offers a unique approach for the treatment of cancer. In fact, transfer of genes encoding immunostimulatory cytokines has been used with remarkable success to eliminate cancer growth in animals. This is based in part, on the fact that chemokines regulate leukocyte adhesion, trafficking, homing and angiogenesis, and contribute to lymphopoiesis and hematopoiesis. Chemokines also play important roles in immune reactions by their involvement in the inflammatory response and their capacity to chemoattract leukocytes. By now, more than 50 chemokines have been well characterized. Furthermore, several chemokine-based immunogene therapies demonstrated strong antitumor effects in preclinical models suggesting that chemokine gene transfer represents a potentially potent approach to suppress tumor growth. In several studies, cytokine genes have been introduced into tumor cells in an attempt to provide a tumor microenvironment that favors innate and/or acquired immune mechanisms to prevent or reverse tumor development. In particular, chemokine gene transfer offers the possibility to trigger the recruitment of initiators or effectors of the immune response within the tumor. Thus, tumor cells that were transduced with CCL3 had reduced tumorigenicity and significantly increased infiltration by macrophages and neutrophils. CCL5 and lymphotactin inhibited tumor formation and generated tumor immunity. CCL2/MCP-1 was shown to reduce in vivo growth of tumor cells and to increase infiltration of macrophages/monocytes into the 
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CX3CL1/Fractalkine is a unique CX3C chemokine acting as an adhesion molecule in its membrane form and behaving as a true chemokine in its soluble form. It serves as a potent chemoattractant for monocytes, NK cells and T lymphocytes. The role of FK gene therapy was investigated in several studies. Thus, the FK gene was transduced into murine Lewis lung carcinoma cells and could induce antitumor immunity through chemoattraction and activation of T cells, DC and NK cells. 28, 29 Murine colon adenocarcinoma cells C26 and melanoma B16F10 cells showed that antitumor immune response induced by FK gene transfer depended on NK and T cells. 30 However, Lavergne et al. 31 reported that in the EL-4 lymphoma model, FK-mediated antitumor effects occurred only via NK cells but not T cells because this antitumor effect was observed only in T cell-and B cell-deficient Rag1-/-mice, but was ablated in NK Cr-release assay using parental MM45T.Li cells as target cells at different E/T ratios. The syngeneic mastocytoma P815 cell line was used for control target cells. CTL activities in mice vaccinated with MM45T.Li-FK increased significantly when compared to that of mice vaccinated with MM45T.Li-mock or MM45T.Li cells at a ratio of 50:1 (Po0.01).
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L Tang et al cell-deficient beige mice. Another study showed that no significant antitumor effect of FK was found when using an ex vivo gene transfer into OVHM tumor cells by an adenoviral vector. + T lymphocytes that were observed in the tumor tissues could be T helper 1 cells and further enhance the cytotoxicity of CD8 + T cells through sensitizing tumor cells to such CTLs by secretion of IFN-g. In summary, the result of these experiments led us to conclude that T cells play a key role in antitumor effects induced by FK. In fact, FK could not only chemoattract T cells but also adhere to T cells and thereby possibly elicited an even more potent tumor rejection.
In conclusion, we could demonstrate for the first time the strong antitumor effects of FK induced by FK genemodified tumor cells, which could chemoattract and activate T cells and are capable of inducing protective immunity and a potent CTL response. In view of these observations, FK should be regarded as a potentially suitable molecule for cancer immunoprevention or gene therapy.
Materials and methods
Animals and cell line
Female BALB/c (H-2 d ), 6-8 weeks of age, were purchased from the Experimental Animal Center of Chongqing Medical University, (Chongqing, China). MM45T.Li, a murine HCC cell line derived from BALB/c mice(H-2 d ), were maintained in RPMI-1640 medium supplemented with 10% heat-inactivated Fetal bonine serum (FBS) (HyClone, Logan, UT, USA), 100 mg/ml streptomycin, 100 U/mL penicillin. All culture media were purchased from Gibco-BRL (Gaithersburg, MD, USA).
Construction of FK expression vector
The coding sequence of murine FK was amplified by RT-PCR from total RNA of the murine breast cancer cell line D2F2. Total RNA was extracted by using RNeasy Mini Kit (Qiagen, Valencia, CA, USA) and used as templates for RT-PCR (951C for 50 s, 561C for 60 s, 721C for 60 s, 30 cycles) using primers 5 0 -PrimerGCTAGCATGGCT CCC TCG CCG CTC GCG-3 0 (upstream) to which NheI site was added and 5 0 -PrimerATG CAG GAC CAC GGT CAC ACT TGC GCA-3 0 (downstream) to which MluI site was added. Then the products were ligated into pCR2.1-TOPO vector through A-T clone (Invitrogen, Carlsbad, CA, USA) and sequenced with M13rev/ T7. The correct clone was digested with NheI and MluI and further cloned into pIRES (BD Clonetech, Mountain View, CA, USA) in order to construct the FK-expressing vector pIRES -FK, pIRES, which was used as mock control. Gene transfer of MM45T.Li. cells with pIRES-FK and pIRES-mock was performed by using LipofectAMINE (Invitrogen, Carlsbad, CA, USA). MM45T.Li cells were transfected in a six-well plate once the cells reached 90-95% confluence. Solution A was prepared by addition of 4 mg of pIRES-FK or pIRES-mock to 250 ml serum-free medium, and solution B by addition of 10 ml liposome to 100 ml serum-free medium. Solutions A and B were mixed at room temperature for 30 min, and added to the washed cells. The medium was replaced with fresh and complete medium 6 h after transfection. Fresh media containing 10% FBS and 700 mg/ml G418 (SigmaAldrich, St Louis, MO, USA) was added (48 h later). The G418 selection continued for a total of 4 weeks and the positive clones obtained were named MM45T.Li-FK and MM45T.Li -mock, respectively. 
In vitro chemotaxis assay
Approximately 1 Â 10 7 splenocytes were resuspended in 0.1 ml of RPMI1640 medium containing 0.5% FBS and loaded into the upper well of a transwell chamber (Costar, Cambridge, MA, USA). The lower wells were filled with 0.6 ml of supernatants of MM45T.Li, MM45T.Li-mock or MM45T.Li-FK, which were harvested after 48 h culture. The chamber was incubated for 4 h at 371C and cells that had migrated through the polycarbonate membrane were harvested from the lower chamber and counted under a microscope. The assay was performed in triplicate and the results expressed as the mean7SE. H-TdR (Amersham, Burkinghamshire, UK) was added, followed by incubation at 371C and 5% CO 2 for 12 h and counting of incorporated radioactivity. 
Assay for cytokine production by the spleen
The cytokine productions in the spleens were determined 14d after inoculation with 5 Â 10 5 MM45T.Li-FK, MM45T.Li -mock cells or parental MM45T.Li cells. Spleen cells were adjusted to a concentration of 1 Â 10 7 cells/ml and grown in round-bottom microwell plates in RPMI 1640. Cells were added to 96-well plates in triplicate for culture with ultrasonic wave-treated MM45T.Li (1 Â 10 5 / ml). The cells were incubated at 371C, 5% CO 2 in an incubator. Supernatants were harvested after 48 h and stored frozen at À801C until assay. Cytokine (IL-2, IFN-g and IL-4) production by spleen cells was measured by a sandwich ELISA using paired mAbs (Jingmei Biotech. Ltd., Shenzhen, China) according to the manufacture's instruction.
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Histology and immunohistochemical analysis of tumor
After inoculation with either 5 Â 10 5 MM45T.Li-FK, MM45T.Li -mock cells or parental MM45T.Li cells, the tumor-bearing mice were killed after 14 days and tumor nodules fixed in neutral-buffered formalin, embedded in paraffin, sectioned and mounted on slides. Sections were stained with H&E. Immunohistochemistry was performed with the method of SP. After being deparaffinized, endogenous peroxidase activity was quenched with 3% H 2 O 2 for 5 min. After being blocked with horse serum, the sections were incubated with goat anti-mouse FK polyclonal antibody (Santa Cruz Biotechnology, Santa Cruz, CA, USA) or rat anti-mouse CD4/CD8 mAbs (BD Pharmingen, San Diego, CA, USA) at 371C for 60 min and then sequentially incubated with optimal dilutions of biotinylated rabbit anti-goat/rat IgG and streptavidin-HRP to be stained with a DAB substrate kit. Slides were then counterstained with hematoxylin for 1 min, and after dehydration, the slides were fixed with coverslip.
Statistical analysis
The data are presented as mean7SE. Statistical analysis was performed using Student's t-test. Statistical significance was determined at PX0.05.
